Trial Profile
A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT, 2% IN PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS
Status:
Discontinued
Phase of Trial:
Phase III/IV
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary) ; Hydrocortisone butyrate; Hydrocortisone butyrate; Pimecrolimus; Pimecrolimus
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 12 Feb 2021 Status changed from active, no longer recruiting to discontinued.
- 24 Dec 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 03 Dec 2020 Status changed from recruiting to active, no longer recruiting.